<DOC>
	<DOCNO>NCT00750113</DOCNO>
	<brief_summary>Patients uncontrolled poorly control hypertension risk experience cardiovascular event myocardial infarction stroke . To reduce risk appropriate antihypertensive therapy allow reach target blood pressure le 130/80 mmHg order maximise cardiovascular protection.The purpose study evaluate efficacy blood pressure control anti-hypertensive therapy initiate combination low dose Nifedipine GITS Telmisartan compare regimen start monotherapy add drug.The primary efficacy parameter 24 hour mean systolic Blood Pressure Ambulatory Blood Pressure Monitoring ( ABPM ) 16 week treatment compare baseline</brief_summary>
	<brief_title>Study Evaluating Efficacy Nifedipine GITS - Telmisartan Combination Blood Pressure Control .</brief_title>
	<detailed_description />
	<mesh_term>Nifedipine</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Hypertension ( office systolic blood pressure &gt; 135 mmHg ) , untreated poorly control stable antihypertensive regimen &gt; /= 4 week Presence type 2 diabetes mellitus target organ damage ( echocardiographic electrocardiographic leave ventricular hypertrophy microalbuminuria ) Presence metabolic syndrome , i.e least two follow [ ( letter ( ) letter ( ) ] patient organ damage least one follow [ letter ( b ) letter ( ) ] patient diabetes mellitus : ( ) impair glucose tolerance ( fast plasma glucose 110 125 mg/dl ) ( b ) raise serum triglyceride ( &gt; /= 150 mg/dl ) comitant use statins indication ( c ) low HDL cholesterol ( male : &lt; 40 mg/dl , female : &lt; 50 mg/dl ) ( ) waist circumference &gt; 102 cm men &gt; 88 cm woman Age : 1875 year Negative pregnancy test female Written inform consent Concomitant treatment AT1antagonists e.g . losartan , eprosartan , telmisartan ) calciumantagonists ( e.g . amlodipine , felodipine , isradipine , nifedipine , nimodipine ) . Concomitant treatment antihypertensive medication safely withdrawn entry ( i.e take stable regimen &gt; /= 4 week ) wo n't possibly keep stable whole duration study . Concomitant treatment know cytochrome P4503A4 inhibitor ( e.g cimetidine , antiHIV protease inhibitor e.g . ritonavir , azole antimycotic eg . Ketoconazole , digoxin , quinidine , tacrolimus ) inducer antiepileptic drug ( eg . phenytoin , carbamazepine phenobarbitone ) rifampicin Concomitant treatment potassium sparingdiuretics . Malignant , severe labile essential hypertension , orthostatic hypotension Cardiovascular shock Evidence secondary form hypertension , include coarctation aorta , hyperaldosteronism , renal artery stenosis pheochromocytoma Myocardial infarction unstable angina within previous 12 month Severe cardiac valve disease Severe rhythm conduction disorder : Cerebrovascular ischaemic event ( stroke , transient ischaemic attack ) within previous 12 month History intracerebral haemorrhage subarachnoid haemorrhage within previous 12 month Type 1 diabetes mellitus Proteinuria ( determine uristix ) BMI &gt; 34 Uncorrected hypokalemia hyperkalemia , potassium outside range 3.0 5.5 mmol/l Sodium depletion and/or hypovolemia Gastrointestinal disease result potential malabsorption ) Liver disease transaminase ( AST , ALT ) level &gt; 3 x upper limit normal range . Renal failure , creatinine &gt; 2.0 mg/dl General malignant disease require treatment within last five year , dementia psychosis , history noncompliance , alcoholism drug abuse , treatment investigational drug 30 day prior enter study , pregnancy lactation , know state allergy hypersensitivity nifedipine dihydropyridine telmisartan , surgical medical condition discretion investigator place subject high risk his/her participation study likely prevent subject comply requirement study complete trial period , history non compliance medical regimen subject unwilling comply study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>